Medical use
Riluzole was approved in the United States for the treatment of ALS by the FDA in 1995[3]. It was created by French pharmaceutical giant Rhone Poulenc Rorer, now known as Sanofi.
There has been some evidence to show that higher doses might produce more significant improvements in ALS patients but at almost £6 (US$10) per tablet it is at risk of being prohibitively expensive given the modest benefit to patients.
One study in the Netherlands found that riluzole is metabolized differently by males and females, and its levels in plasma are decreased in patients who smoke cigarettes or take omeprazole. A Cochrane Library review states a 9% gain in the probability of surviving one year.
Riluzole (marketed as Rilutek and Teglutik) is a drug used to treat amyotrophic lateral sclerosis. Riluzole delays the onset of ventilator-dependence or tracheostomy in selected patients and may increase survival by approximately two to three months.
Riluzole is available in a tablet and liquid form. The liquid formulation may be more suitable for patients with swallowing difficulties.
You must be logged in to post a review.
Reviews
There are no reviews yet.